- Home
- WFG vs BPMC Comparison
WFG vs BPMC Comparison
Compare WFG & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFG
- BPMC
- Stock Information
- Founded
- WFG 1955
- BPMC 2008
- Country
- WFG Canada
- BPMC United States
- Employees
- WFG N/A
- BPMC N/A
- Industry
- WFG
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- WFG
- BPMC Health Care
- Exchange
- WFG Nasdaq
- BPMC Nasdaq
- Market Cap
- WFG 7.5B
- BPMC 6.7B
- IPO Year
- WFG N/A
- BPMC 2015
- Fundamental
- Price
- WFG $89.95
- BPMC $110.05
- Analyst Decision
- WFG Buy
- BPMC Buy
- Analyst Count
- WFG 3
- BPMC 19
- Target Price
- WFG $111.67
- BPMC $122.72
- AVG Volume (30 Days)
- WFG 143.2K
- BPMC 833.0K
- Earning Date
- WFG 02-12-2025
- BPMC 02-13-2025
- Dividend Yield
- WFG 1.42%
- BPMC N/A
- EPS Growth
- WFG N/A
- BPMC N/A
- EPS
- WFG N/A
- BPMC N/A
- Revenue
- WFG $6,283,000,000.00
- BPMC $434,415,000.00
- Revenue This Year
- WFG N/A
- BPMC $108.09
- Revenue Next Year
- WFG $6.75
- BPMC $39.34
- P/E Ratio
- WFG N/A
- BPMC N/A
- Revenue Growth
- WFG N/A
- BPMC 100.93
- 52 Week Low
- WFG $73.91
- BPMC $72.24
- 52 Week High
- WFG $102.40
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- WFG 54.81
- BPMC 69.83
- Support Level
- WFG $86.81
- BPMC $103.67
- Resistance Level
- WFG $89.73
- BPMC $107.88
- Average True Range (ATR)
- WFG 2.16
- BPMC 4.21
- MACD
- WFG 0.57
- BPMC 2.22
- Stochastic Oscillator
- WFG 87.14
- BPMC 99.08
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board, or OSB, producers in the world.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.